phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

MedMon_Catalyst_Banner-2.jpg

In case you missed it, earlier this month, the Center for Medicare & Medicaid Services formally withdrew a controversial proposal that would have had a detrimental impact on patient access to lifesaving treatments covered under Part B, many of which are used to treat complex conditions like cancer, rheumatoid arthritis and mental illness.

Originally put forward by the Center for Medicare and Medicaid Innovation (CMMI) in March 2016, the Part B Drug Payment Model, or Part B demo, proposed altering the way providers are reimbursed under Part B with a nearly nationwide, mandatory model that threatened access and quality of care for Medicare patients.

CMMI has broad authority to test new models of paying for and delivering care in Medicare, Medicaid and the Children's Health Insurance Program, and the Part B demo elevated concerns over its flexibility to make far-reaching changes. Hundreds of patients, doctors and policymakers from across the aisle expressed concerns about the proposal, with many saying it marked a radical departure from CMMI’s previous demonstrations.

The withdrawal of the Part B demo and a recent request for feedback from stakeholders on the future of the agency mark steps in the right direction for CMMI. Before issuing any new demos, CMMI should carefully consider the feedback received as part of this process.

Without appropriate safeguards, CMMI programs could negatively impact millions of Medicare beneficiaries.

Learn more about CMMI at PhRMA.org/CMMI.

Nicole Longo

Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Nicole Longo

Author Twitter

Author LinkedIn

What AARP isn’t telling seniors about MFN

August 24, 2026

CMS proposal could discourage patient-centered innovation

August 18, 2026

Nearly 1 in 4 patients initially denied access to IRA medicines

August 6, 2026

Medicare Part D at 20: Building on a strong foundation

July 23, 2026

"Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI"

Medicare

CMMI

Part B

Medicare Monday

Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI

October 30, 2017

"Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI"

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list